ViaCyte   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1999)
Status: Acquired by Vertex (2022) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2005
NCT00260234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novocell | ViaCyte | ViaCyte, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

allogeneic pancreatic islet cells (1 trial)

pec-01 cells (3 trials)

vctx211 (1 trial)

Drugs in Phase 1 Trials (1)

vctx210a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Hypoglycemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4